These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257 [TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
7. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731 [TBL] [Abstract][Full Text] [Related]
8. Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer. Burfeind KG; Zhu X; Norgard MA; Levasseur PR; Huisman C; Buenafe AC; Olson B; Michaelis KA; Torres ER; Jeng S; McWeeney S; Raber J; Marks DL Elife; 2020 May; 9():. PubMed ID: 32391790 [TBL] [Abstract][Full Text] [Related]
9. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma. Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673 [TBL] [Abstract][Full Text] [Related]
10. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393 [TBL] [Abstract][Full Text] [Related]
11. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Luo H; Ikenaga N; Nakata K; Higashijima N; Zhong P; Kubo A; Wu C; Tsutsumi C; Shimada Y; Hayashi M; Oyama K; Date S; Abe T; Ideno N; Iwamoto C; Shindo K; Ohuchida K; Oda Y; Nakamura M J Exp Clin Cancer Res; 2024 Sep; 43(1):258. PubMed ID: 39261943 [TBL] [Abstract][Full Text] [Related]
12. Neutrophil in the Pancreatic Tumor Microenvironment. Jin L; Kim HS; Shi J Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439836 [TBL] [Abstract][Full Text] [Related]
13. A Small Molecule CCR2 Antagonist Depletes Tumor Macrophages and Synergizes with Anti-PD-1 in a Murine Model of Cutaneous T-Cell Lymphoma (CTCL). Wu X; Singh R; Hsu DK; Zhou Y; Yu S; Han D; Shi Z; Huynh M; Campbell JJ; Hwang ST J Invest Dermatol; 2020 Jul; 140(7):1390-1400.e4. PubMed ID: 31945344 [TBL] [Abstract][Full Text] [Related]
14. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Nielsen SR; Strøbech JE; Horton ER; Jackstadt R; Laitala A; Bravo MC; Maltese G; Jensen ARD; Reuten R; Rafaeva M; Karim SA; Hwang CI; Arnes L; Tuveson DA; Sansom OJ; Morton JP; Erler JT Nat Commun; 2021 Jun; 12(1):3414. PubMed ID: 34099731 [TBL] [Abstract][Full Text] [Related]
15. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer. Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647 [TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H Front Immunol; 2018; 9():1878. PubMed ID: 30158932 [TBL] [Abstract][Full Text] [Related]
18. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer. Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087 [TBL] [Abstract][Full Text] [Related]
19. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Di Caro G; Cortese N; Castino GF; Grizzi F; Gavazzi F; Ridolfi C; Capretti G; Mineri R; Todoric J; Zerbi A; Allavena P; Mantovani A; Marchesi F Gut; 2016 Oct; 65(10):1710-20. PubMed ID: 26156960 [TBL] [Abstract][Full Text] [Related]
20. IFNα-induced BST2 Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]